- In elderly patients with chronic lymphocytic leukemia (CLL), ibrutinib was not associated with a significantly higher risk for hematologic adverse events (AEs) comprising anemia, thrombocytopenia, neutropenia, or febrile neutropenia vs other treatments.
- Ibrutinib was tied to a higher risk for abdominal manifestations, including vomiting, abdominal pain, constipation, and diarrhea.
Why this matters
- CLL is mainly diagnosed in elderly male patients.
- Meta-analysis to investigate ibrutinib-associated AEs in elderly patients with CLL.
- A search of medical publications databases yielded 5 applicable studies including 2456 patients with CLL: 1113 received ibrutinib and 1343 were considered nonibrutinib control patients.
- Mean age: 68.8 years in ibrutinib-treated patients; 68.0 years in control patients.
- Funding: None.
- Ibrutinib-treated patients demonstrated no significant increase in risk for:
- Anemia: risk ratio (RR), 0.90; 95% CI, 0.67-1.21; P=.49.
- Thrombocytopenia: RR, 0.61; 95% CI, 0.32-1.14; P=.12.
- Neutropenia: RR, 0.50; 95% CI, 0.25-1.00; P=.05.
- Febrile neutropenia: RR, 0.89; 95% CI, 0.32-2.49; P=.83.
- Risk for respiratory tract infection was comparable in ibrutinib-treated patients and control patients: RR, 1.01; 95% CI, 0.78-1.30; P=.96.
- Ibrutinib-treated patients had significantly elevated risk for:
- Abdominal manifestations: RR, 1.62; 95% CI, 1.32-2.00; P=.00001.
- Diarrhea: RR, 2.14; 95% CI, 1.44-3.17; P=.0002.
- Control group received a range of different therapies.
- Bleeding events not captured.